SPOTLIGHT -
Risk of Lifestyle Diseases for Patients With Schizophrenia
Improving physical activity levels and eating habits could help patients with schizophrenia.
Medicine Combination With the Potential to Beat Methamphetamine Use Disorder
In an ADAPT-2 study, a combination of injectable naltrexone and oral bupropion showed promise for methamphetamine users.
Positive Results From Trial of Risperidone Injectable Schizophrenia Treatment
The RISE study results look promising.
Psychiatry Responds to the Violence at the Capitol
Major psychiatry organizations condemn the actions and events of January 6th.
Medication for Agitation in Dementia and Alzheimer Disease Patients Moves Forward
A new formulation of dexmedetomidine meets primary and secondary endpoints in recently completed study.
Developments in Trials of a New OCD Treatment
A new phase 3 trial recently started for the novel treatment troriluzole.
Breakthroughs in Alzheimer Disease
New developments in Alzheimer disease treatment and research.
A Transdermal System for the Treatment of Schizophrenia
The first and only transdermal patch for the treatment of adults with schizophrenia shows positive phase 3 trial results.
Korean Intellectual Property Office Grants Patent Application for Depression Treatment
VistaGen Therapeutic’s grant application for PH10, an investigational therapeutic agent for the treatment of depression, has been approved.
Schizophrenia in the News
Findings bring us closer to understanding schizophrenia that may enable clinicians to target symptoms.
Drug for Treatment of Major Depressive Disorder Announces Positive Trial Results
Axsome Therapeutics released details from their COMET-SI trial for AXS-05, an oral investigational NMDA receptor.
Promising New Data Announced on In-the-Works Schizophrenia Treatment
Karuna Therapeutics shared exciting results from a Phase 2 trial on their lead agent.
Holiday Gifts with Mental Wellness in Mind
Looking for holiday gifts that encourage mental well being?
The Need for LGBTQ and Gender-Affirming Spaces
A new study by The Trevor Project finds that welcoming environments can reduce suicide risk.
Less Risky Than Believed: Alcohol and Cannabis Combinations
According to a recent study, certain product combinations of alcohol and cannabis may be less likely to cause negative consequences.
How Does Your Salary Stack Up Against Your Colleagues?
Let's talk about money...
Defective Cilia in the Brain Linked to Schizophrenia
Mutations in PCM1, a gene crucial to neuronal cilia function, have been connected with schizophrenia, according to a recent study.
One of the First US In Vitro Diagnostic Tests for Assessment of Alzheimer Disease
The Lumipulse® G β-Amyloid Ratio in vitro diagnostic test was filed for 510(k) premarket clearance.
Dlgap2: The Gene Associated With Memory Loss
A new study associates a gene that facilitates neuron communication in the nervous system with memory loss.
Is Child Maltreatment Associated with Substance Use? New Evidence Emerges
Female emergency department patients with adverse childhood experiences were more likely to have substance use issues.
LGBTQ+ Individuals who Abuse Substances Are More Likely to Have Psychiatric Disorders
Sexual minorities with alcohol and tobacco addictions are at a higher risk for comorbid psychiatric disorders, bisexual women in particular.
Pregnancy and Postpartum Suicide Risk: The New Numbers
Suicide attempts among pregnant or postpartum mothers have nearly tripled over the past decade.
A Shift in the Air: Changes in Young Adults’ Vaping and Substance Use During COVID-19
How has the COVID-19 pandemic affected the way young adults use substances like vaping, alcohol, and marijuana?
Experts Share Clinical Tips and Insights at 2020 Annual Psychiatric Times® World CME Conference™
Key leaders experienced in real-world clinical practice share on a range of topics.
Antidepressant Drug Helps Prevent Deterioration in Patients With COVID-19
Fluvoxamine was not intended as a COVID-19 medication, but a recent study suggests it may help prevent serious complications for patients with COVID-19.
FDA Applies Brakes to Schizophrenia Drug Approval Due to Manufacturing Concerns
Manufacturing issues stall progress with ALKS 3831, Alkermes’s promising new drug for the treatment of schizophrenia and bipolar I disorder.
Helping Young People Diagnosed With Psychosis Develop Identities
New research underlies the need for addressing identity in young patients during early stages of psychosis.
A New Way to “Watch” Your Nightmares
A new prescription smartwatch app may improve sleep quality for those with nightmare disorders.
Deep Transcranial Magnetic Stimulation: A New Solution to Obsessive-Compulsive Disorder
Recently published data suggests a promising new treatment for patients with obsessive-compulsive disorder.
Poster Presentation Sheds Light on Alzheimer Disease Preventative Treatments
Good news in the fight against Alzheimer disease, with major progress in new, innovative treatments.